Rate and predictors of loss to follow-up in HIV care in a low-resource setting: analyzing critical risk periods
Published in Biomedical Research
Why Do Some People Stop HIV Treatment? Understanding the Key Moments
In the global fight against HIV, keeping people engaged in their treatment is crucial. Even though many countries aim to meet ambitious HIV care goals by 2030, a significant challenge remains: helping those who start HIV treatment continue their care and keep their virus under control. A big part of this challenge is what’s known as "loss to follow-up" (LTFU).
What is Loss to Follow-Up (LTFU)?
LTFU happens when someone on HIV treatment misses their medical appointments or stops taking their medication for over 28 days. This is a serious issue, as it can lead to poorer health, increased risk of death, and a higher chance of spreading HIV to others because the virus isn’t being suppressed.
When Do People Stop Treatment?
This study looked at 737 adults who were new to HIV care and identified the times when they were most likely to stop their treatment:
- The First 6 Months Are Critical: About 50% of the people who dropped out of care did so within the first six months. This early period is a high-risk time, with an LTFU rate nine times higher than later periods (13-24 months). People might face challenges like dealing with side effects, struggling to adjust to a new routine, or not yet seeing the benefits of the medication.
- 7-12 Months: A Continued Risk: Even though the risk of dropping out decreases after the first six months, many people still struggle to stick with their treatment during months 7-12. About 30% of those who stopped care did so during this time. Factors like financial difficulties, stigma, or transportation issues can continue to affect them.
- After 12 Months: A More Stable Phase: After a year on treatment, the dropout rate drops significantly. By this time, many patients have adjusted to their routine, seen improvements in their health, and are more committed to their treatment.
What Can We Do About It?
The findings suggest that the first six months of HIV treatment are a make-or-break time. Health programs should focus on providing extra support during this period, such as helping patients manage side effects and offering counseling. Continued support is also important in the following months to help people overcome challenges that might come up later.
Follow the Topic
-
BMC Infectious Diseases
This journal is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of infectious and sexually transmitted diseases in humans, as well as related molecular genetics, pathophysiology, and epidemiology.
Related Collections
With Collections, you can get published faster and increase your visibility.
Infectious disease management in infants and children
BMC Infectious Diseases invites submissions for a Collection on Infectious diseases in infants and children.
Infectious diseases in infants and children represent a significant burden on healthcare systems globally, often leading to serious complications, long-term health issues, and even mortality. This Collection aims to explore the diverse range of infectious diseases that specifically affect the pediatric population, including but not limited to respiratory infections, gastrointestinal infections, and vaccine-preventable diseases. Understanding the unique immune responses and vulnerabilities of young children is crucial for developing effective prevention and treatment strategies tailored to their needs.
The continued research into pediatric infectious diseases is vital for several reasons. Advances in immunization have significantly reduced the incidence of many vaccine-preventable diseases; however, challenges remain, particularly with the emergence of antimicrobial resistance and the resurgence of certain infections. Furthermore, the COVID-19 pandemic has underscored the importance of infection control measures in childcare, preschool, and school settings and highlighted the need for ongoing surveillance of childhood diseases. This area of research promises to contribute to improved health outcomes for infants and children worldwide.
With sustained research efforts, we can anticipate significant advances in the future, including the development of novel vaccines, improved diagnostics, and tailored treatment protocols. Continued exploration of the epidemiology of childhood diseases will further enhance our understanding of transmission dynamics and inform public health interventions.
We invite pediatricians, infectious disease specialists, public health professionals, immunologists, epidemiologists, and researchers in related fields to contribute original research articles on topics including but not limited to:
- Pediatric infectious diseases and their management
- Early childhood immunity and its implications
- Epidemiology of respiratory infections in children
- Antimicrobial resistance trends in pediatric settings
- Infection control in childcare, preschool, and school settings
This Collection supports and amplifies research related to SDG 3: Good Health and Well-being.
All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.
Publishing Model: Open Access
Deadline: Jun 30, 2026
Hepatitis virus infections and treatment
BMC Infectious Diseases invites submissions for a Collection on Hepatitis virus infections and treatment.
Hepatitis virus infections—including types A, B, C, D, and E—remain a significant global public health concern, collectively affecting hundreds of millions of people and contributing to a wide spectrum of liver-related diseases. These range from acute hepatitis and chronic liver inflammation to cirrhosis and hepatocellular carcinoma. Each hepatitis virus presents unique challenges in terms of transmission, disease progression, and treatment, with varying impacts across different regions and populations.
While hepatitis C has seen transformative progress with the development of Direct-Acting Antivirals (DAAs), hepatitis B continues to pose challenges due to its chronic nature and the need for lifelong management. Hepatitis A and E, typically transmitted via the fecal-oral route, are preventable through improved sanitation and vaccination, yet outbreaks still occur in resource-limited settings. Hepatitis D, which only occurs in conjunction with hepatitis B, adds complexity to diagnosis and treatment strategies.
Recent advances in diagnostics, therapeutics, and public health interventions have improved outcomes for many affected individuals. However, disparities in access to care, limited awareness, and gaps in screening and vaccination programs hinder global efforts to eliminate viral hepatitis as a public health threat. Continued research is essential to develop more effective prevention strategies, enhance treatment protocols, and understand the epidemiological and clinical nuances of each hepatitis virus. This Collection welcomes research that explores:
- Innovations in antiviral therapies across hepatitis types
- Epidemiology and transmission dynamics of hepatitis A–E
- Vaccine development and implementation strategies
- Novel diagnostic tools for acute and chronic hepatitis
- Public health approaches to hepatitis prevention and control
- Clinical implications of co-infections (e.g., HBV/HDV)
This Collection supports and amplifies research related to SDG 3: Good Health and Well-being.
All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.
Publishing Model: Open Access
Deadline: Jul 20, 2026
Please sign in or register for FREE
If you are a registered user on Research Communities by Springer Nature, please sign in